AR079746A1 - Formulacion farmaceutica de anticuerpo - Google Patents
Formulacion farmaceutica de anticuerpoInfo
- Publication number
- AR079746A1 AR079746A1 ARP100104954A ARP100104954A AR079746A1 AR 079746 A1 AR079746 A1 AR 079746A1 AR P100104954 A ARP100104954 A AR P100104954A AR P100104954 A ARP100104954 A AR P100104954A AR 079746 A1 AR079746 A1 AR 079746A1
- Authority
- AR
- Argentina
- Prior art keywords
- stabilizer
- formula according
- polysorbate
- antibody
- igg class
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 6
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 abstract 4
- 239000006172 buffering agent Substances 0.000 abstract 3
- 229960002885 histidine Drugs 0.000 abstract 3
- 239000004094 surface-active agent Substances 0.000 abstract 3
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 abstract 2
- 229930006000 Sucrose Natural products 0.000 abstract 2
- 229930182817 methionine Natural products 0.000 abstract 2
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 abstract 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 abstract 2
- 229920000053 polysorbate 80 Polymers 0.000 abstract 2
- 229940068968 polysorbate 80 Drugs 0.000 abstract 2
- 239000005720 sucrose Substances 0.000 abstract 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 abstract 1
- DPVHGFAJLZWDOC-PVXXTIHASA-N (2r,3s,4s,5r,6r)-2-(hydroxymethyl)-6-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxane-3,4,5-triol;dihydrate Chemical compound O.O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DPVHGFAJLZWDOC-PVXXTIHASA-N 0.000 abstract 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 abstract 1
- 229920001213 Polysorbate 20 Polymers 0.000 abstract 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 abstract 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 abstract 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 abstract 1
- 239000008351 acetate buffer Substances 0.000 abstract 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 abstract 1
- 229960003589 arginine hydrochloride Drugs 0.000 abstract 1
- 239000000872 buffer Substances 0.000 abstract 1
- 150000001720 carbohydrates Chemical group 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 abstract 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 abstract 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 abstract 1
- 229920000136 polysorbate Polymers 0.000 abstract 1
- 229950008882 polysorbate Drugs 0.000 abstract 1
- 229940068977 polysorbate 20 Drugs 0.000 abstract 1
- 235000017281 sodium acetate Nutrition 0.000 abstract 1
- 239000001632 sodium acetate Substances 0.000 abstract 1
- 229960004793 sucrose Drugs 0.000 abstract 1
- -1 sucrose dihydrate Chemical class 0.000 abstract 1
- 229940074410 trehalose Drugs 0.000 abstract 1
- 229940074409 trehalose dihydrate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39591—Stabilisation, fragmentation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Reivindicacion 1: Formulacion farmacéutica, que comprende 1 a 200 mg/ml de un anticuerpo anti-EGFR de clase IgG, 1 a 100 mM de un agente tamponador, 0,001% a 1% (p/v) de un surfactante, 1 a 500 mM de por lo menos un estabilizador, a un pH comprendido en el intervalo de entre 4,0 y 7,0. Reivindicacion 2: Formulacion segun la reivindicacion 1, en la que la concentracion de anticuerpo anti-EGFR de clase IgG se encuentra comprendida en el intervalo de entre 1 y 10 mg/ml. Reivindicacion 3: Formulacion segun la reivindicacion 1 o 2, en la que el agente tamponador es un tampon histidina o un tampon acetato. Reivindicacion 6: Formulacion segun cualquiera de las reivindicaciones 1 a 5, en la que el surfactante es un polisorbato. Reivindicacion 12: Formulacion segun cualquiera de las reivindicaciones 1 a 11, que comprende: 5 a 50 mg/ml de un anticuerpo anti-EGFR de clase IgG, un agente tamponador 15 a 30 mM, seleccionado de entre L-histidina y acetato sodico, un surfactante al 0,02-0,05% (p/v), seleccionado de entre polisorbato 20 y polisorbato 80, por lo menos un estabilizador 120 a 300 mM, seleccionado de entre dihidrato de trehalosa, sacarosa, hidrocloruro de arginina y cloruro sádico, opcionalmente, metionina 5 a 25 mM como segundo estabilizador, a un pH de 5,5 +- 0,3. Reivindicacion 14: Formulacion segun cualquiera de las reivindicaciones 1 a 13, que comprende 20 a 50 mg/ml de mAb anti-EGFR de IgG1 ICR62-hu, L-histidina 20 mM, polisorbato 80 al 0,02-0,03% (p/v), un primer estabilizador 240 mM, en el que dicho primer estabilizador es un sacárido seleccionado de entre dihidrato de trehalosa y sacarosa, metionina 10 mM como segundo estabilizador, a un PH de 5,5 +- 0,3. Reivindicacion 16: Formulacion segun cualquiera de las reivindicaciones 1 a 15, en la que el anticuerpo EGFR de clase IgG es mAb anti-EGFR de IgG1 ICR62-hu.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09180840 | 2009-12-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR079746A1 true AR079746A1 (es) | 2012-02-15 |
Family
ID=43618150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100104954A AR079746A1 (es) | 2009-12-29 | 2010-12-27 | Formulacion farmaceutica de anticuerpo |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US20110158987A1 (es) |
| EP (1) | EP2519262A2 (es) |
| JP (1) | JP2013515754A (es) |
| KR (1) | KR20120110175A (es) |
| CN (1) | CN102686241A (es) |
| AR (1) | AR079746A1 (es) |
| AU (1) | AU2010338305A1 (es) |
| BR (1) | BR112012013148A2 (es) |
| CA (1) | CA2783715A1 (es) |
| IL (1) | IL219592A0 (es) |
| MX (1) | MX2012007676A (es) |
| RU (1) | RU2012131099A (es) |
| SG (1) | SG182304A1 (es) |
| TW (1) | TW201200152A (es) |
| WO (1) | WO2011080209A2 (es) |
| ZA (1) | ZA201204266B (es) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE035774T2 (en) * | 2011-08-12 | 2018-05-28 | Merial Inc | Biological substances, in particular vaccines, preserved by vacuum |
| EP2879712B1 (en) | 2012-07-31 | 2018-04-25 | Crown Bioscience, Inc. (Taicang) | Histological markers for identifying non-small cell lung carcinoma patients for treatment with an anti-egfr drug |
| SMT202000147T1 (it) | 2012-09-07 | 2020-05-08 | Coherus Biosciences Inc | Formulazioni acquose stabili di adalimumab |
| AR093297A1 (es) * | 2012-10-31 | 2015-05-27 | Amgen Res Munich Gmbh | Formulacion liquida que comprende un compuesto neutralizante de gm-csf |
| EP2914289B1 (en) | 2012-10-31 | 2019-05-22 | Takeda GmbH | Lyophilized formulation comprising gm-csf neutralizing compound |
| UA117466C2 (uk) | 2012-12-13 | 2018-08-10 | Мерк Шарп Енд Доме Корп. | СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19 |
| EP2968538A1 (en) * | 2013-03-15 | 2016-01-20 | Bayer HealthCare LLC | Anti-prolactin receptor antibody formulations |
| WO2014144549A1 (en) | 2013-03-15 | 2014-09-18 | Biogen Idec Ma Inc. | Factor ix polypeptide formulations |
| KR20220045064A (ko) | 2013-08-30 | 2022-04-12 | 다케다 야쿠힌 고교 가부시키가이샤 | 류마티스성 관절염의 치료에서 또는 진통제로서 사용하기 위한 gm-csf 중화 항체 |
| AU2015217572B2 (en) | 2014-02-11 | 2020-10-15 | Visterra, Inc. | Antibody moleules to dengue virus and uses thereof |
| WO2015134406A1 (en) * | 2014-03-03 | 2015-09-11 | La Jolla Biologics, Inc. | Stable aqueous recombinant protein formulations |
| KR102385802B1 (ko) | 2014-05-07 | 2022-04-13 | 다케다 야쿠힝 고교 가부시키가이샤 | Gm-csf 중화 화합물을 포함하는 액체 제제 |
| CN105651848A (zh) * | 2014-11-13 | 2016-06-08 | 浙江海正药业股份有限公司 | 一种含有保护剂的毛细管凝胶电泳检测试剂盒 |
| AR103173A1 (es) | 2014-12-22 | 2017-04-19 | Novarits Ag | Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17 |
| KR101776879B1 (ko) | 2015-01-19 | 2017-09-08 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| BR112017023867A2 (pt) | 2015-05-07 | 2018-07-24 | Novimmune Sa | métodos e composições para diagnóstico e tratamento de distúrbios em pacientes com níveis elevados de cxcl9 e outros biomarcadores |
| US11091543B2 (en) | 2015-05-07 | 2021-08-17 | Swedish Orphan Biovitrum Ag | Methods, compositions and dosing regimens for treating or preventing interferon-gamma related indications |
| UA124259C2 (uk) * | 2015-09-28 | 2021-08-18 | Сужоу Санкадіа Байофармасьютікалз Ко., Лтд. | Фармацевтичне одержання стабільного анти-pd-1 антитіла та його застосування в медицині |
| US11229702B1 (en) | 2015-10-28 | 2022-01-25 | Coherus Biosciences, Inc. | High concentration formulations of adalimumab |
| US11058769B2 (en) * | 2015-12-07 | 2021-07-13 | Merck Patent Gmbh | Aqueous pharmaceutical formulation comprising anti-PD-L1 antibody Avelumab |
| JP7155009B2 (ja) * | 2016-03-25 | 2022-10-18 | ビステラ， インコーポレイテッド | デングウイルスに対する抗体分子の製剤 |
| WO2017184880A1 (en) | 2016-04-20 | 2017-10-26 | Coherus Biosciences, Inc. | A method of filling a container with no headspace |
| IT201600077232A1 (it) * | 2016-07-22 | 2018-01-22 | Bio Optica Milano S P A | Una preparazione liquida acquosa per la conservazione di un campione istologico |
| EP3504241B1 (en) * | 2016-08-29 | 2024-05-15 | Tiziana Life Sciences PLC | Anti-cd3 antibody formulations |
| CN107773755B (zh) * | 2016-08-31 | 2021-06-22 | 上海津曼特生物科技有限公司 | 抗表皮生长因子受体单克隆抗体的注射液制剂 |
| CA3037440A1 (en) * | 2016-09-27 | 2018-04-05 | Fresenius Kabi Deutschland Gmbh | Liquid pharmaceutical composition |
| CN107987161B (zh) * | 2016-10-26 | 2021-04-16 | 泰州迈博太科药业有限公司 | 一种抗egfr单克隆抗体制剂 |
| JP7382232B2 (ja) | 2017-05-02 | 2023-11-16 | メルク・シャープ・アンド・ドーム・エルエルシー | 抗ｌａｇ３抗体の製剤および抗ｌａｇ３抗体と抗ｐｄ－１抗体との共製剤 |
| JP2020521788A (ja) * | 2017-06-02 | 2020-07-27 | エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト | 免疫アゴニストの投与経路 |
| JP7407699B2 (ja) * | 2017-07-28 | 2024-01-04 | エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト | 二重特異性抗体製剤 |
| KR102208378B1 (ko) * | 2017-08-17 | 2021-01-28 | 주식회사 녹십자 | 항-egfr 항체를 포함하는 약학 제제 |
| GB201719447D0 (en) | 2017-11-23 | 2018-01-10 | Ucb Biopharma Sprl | Pharmaceutical composition |
| BR112020011483A2 (pt) | 2017-12-08 | 2020-11-24 | Argenx Bvba | uso de antagonistas de fcrn para tratamento de miastenia gravis generalizada |
| MX2020013195A (es) | 2018-06-08 | 2021-02-26 | Argenx Bvba | Composiciones y metodos para el tratamiento de la trombocitopenia inmunitaria. |
| CN110960490A (zh) * | 2018-09-28 | 2020-04-07 | 江苏恒瑞医药股份有限公司 | 一种抗egfr抗体偶联药物组合物及其用途 |
| BR112021006055A2 (pt) * | 2018-10-04 | 2021-07-20 | Genmab Holding B.V. | composição farmacêutica, uso da composição farmacêutica, e, métodos para induzir a morte celular ou para inibir o crescimento e/ou proliferação de uma célula tumoral e para tratar um indivíduo. |
| KR20210089215A (ko) | 2018-11-07 | 2021-07-15 | 머크 샤프 앤드 돔 코포레이션 | 항-lag3 항체 및 항-pd-1 항체의 공동-제제 |
| EP3876978A4 (en) * | 2018-11-07 | 2022-09-28 | Merck Sharp & Dohme Corp. | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF |
| CR20210435A (es) | 2019-02-18 | 2021-09-20 | Lilly Co Eli | Formulación de anticuerpos terapéuticos |
| EP3980063A1 (en) * | 2019-06-07 | 2022-04-13 | Argenx BVBA | Pharmaceutical formulations of fcrn inhibitors suitable for subcutaneous administration |
| CU20190104A7 (es) * | 2019-12-17 | 2021-08-06 | Ct Inmunologia Molecular | Formulación estable del anticuerpo nimotuzumab |
| BR112022011775A2 (pt) * | 2019-12-20 | 2022-08-30 | Ares Trading Sa | Composição de proteína de fusão igg:tgfssrii |
| WO2021140202A1 (en) | 2020-01-08 | 2021-07-15 | argenx BV | Methods for treating pemphigus disorders |
| CN113967195A (zh) * | 2020-07-22 | 2022-01-25 | 三生国健药业（上海）股份有限公司 | 抗her2/pd1双特异性抗体冻干制剂及其制备方法 |
| EP4272756A4 (en) * | 2021-02-05 | 2024-12-11 | Bio-Thera Solutions, Ltd. | ANTI-IL-5 ANTIBODY FORMULATION, MANUFACTURING METHOD AND USE THEREOF |
| TW202308689A (zh) * | 2021-04-21 | 2023-03-01 | 美商健生生物科技公司 | 高濃度的雙特異性抗體調配物 |
| KR20250039514A (ko) | 2022-06-15 | 2025-03-20 | 아르젠엑스 비브이 | Fcrn/hsa 결합 분자 및 사용 방법 |
| TWI859943B (zh) * | 2022-06-21 | 2024-10-21 | 大陸商廣東菲鵬製藥股份有限公司 | 一種含抗cd47抗體或其抗原結合片段的製劑及其製備方法和應用 |
| WO2025038671A2 (en) * | 2023-08-15 | 2025-02-20 | Amgen Inc. | Acidic buffered intravenous solution stabilizers for use in methods of treatment |
| TW202523354A (zh) * | 2023-11-29 | 2025-06-16 | 大陸商四川科倫博泰生物醫藥股份有限公司 | 抗體製劑 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6267958B1 (en) * | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| ES2434840T3 (es) * | 1995-07-27 | 2013-12-17 | Genentech, Inc. | Formulación de proteína liofilizada isotónica estable |
| DK1071700T3 (da) | 1998-04-20 | 2010-06-07 | Glycart Biotechnology Ag | Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet |
| US20030104996A1 (en) * | 2001-08-30 | 2003-06-05 | Tiansheng Li | L-methionine as a stabilizer for NESP/EPO in HSA-free formulations |
| ATE556591T1 (de) * | 2001-11-08 | 2012-05-15 | Abbott Biotherapeutics Corp | Stabile pharmazeutische flüssigformulierung von igg-antikörpern |
| ATE475708T1 (de) | 2003-01-22 | 2010-08-15 | Glycart Biotechnology Ag | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion |
| DE10355251A1 (de) * | 2003-11-26 | 2005-06-23 | Merck Patent Gmbh | Pharmazeutische Zubereitung enthaltend einen Antikörper gegen den EGF-Rezeptor |
| DOP2006000022A (es) * | 2005-01-28 | 2006-08-15 | Wyeth Corp | Formulaciones líquidas estabilizadas de polipetidos |
| UA95068C2 (uk) * | 2005-02-07 | 2011-07-11 | Глікарт Біотехнолоджі Аг | Антиген-зв'язуюча молекула, яка зв'язує еgfr, вектор, що її кодує, та їх застосування |
| CN103145841A (zh) * | 2005-06-30 | 2013-06-12 | Abbvie公司 | Il-12/p40结合蛋白 |
| SI1933871T1 (sl) * | 2005-09-07 | 2013-10-30 | Amgen Fremont Inc. | Humana monoklonska protitelesa proti aktivin receptorju podobni kinazi-1 |
| AU2006330858A1 (en) * | 2005-12-21 | 2007-07-05 | Wyeth | Protein formulations with reduced viscosity and uses thereof |
| EP1998806A1 (en) * | 2006-03-28 | 2008-12-10 | F. Hoffmann-Roche AG | Anti-igf-1r human monoclonal antibody formulation |
| KR20090021298A (ko) * | 2006-06-14 | 2009-03-02 | 임클론 시스템즈 인코포레이티드 | 항-ｅｇｆｒ 항체의 동결건조 제제 |
| AR062223A1 (es) * | 2006-08-09 | 2008-10-22 | Glycart Biotechnology Ag | Moleculas de adhesion al antigeno que se adhieren a egfr, vectores que los codifican, y sus usos de estas |
| AU2007309616B2 (en) * | 2006-10-20 | 2011-10-06 | Amgen Inc. | Stable polypeptide formulations |
| AR064220A1 (es) * | 2006-12-11 | 2009-03-18 | Hoffmann La Roche | Formulacion liofilizada mab abeta |
| CA2693611A1 (en) * | 2007-07-10 | 2009-01-15 | F. Hoffmann-La Roche Ag | Novel formulation |
| MY171841A (en) * | 2007-12-21 | 2019-11-04 | Hoffmann La Roche | Antibody formulation |
| US9345661B2 (en) * | 2009-07-31 | 2016-05-24 | Genentech, Inc. | Subcutaneous anti-HER2 antibody formulations and uses thereof |
-
2010
- 2010-12-23 WO PCT/EP2010/070625 patent/WO2011080209A2/en not_active Ceased
- 2010-12-23 SG SG2012048591A patent/SG182304A1/en unknown
- 2010-12-23 KR KR1020127019717A patent/KR20120110175A/ko not_active Ceased
- 2010-12-23 CA CA2783715A patent/CA2783715A1/en not_active Abandoned
- 2010-12-23 MX MX2012007676A patent/MX2012007676A/es not_active Application Discontinuation
- 2010-12-23 US US12/977,509 patent/US20110158987A1/en not_active Abandoned
- 2010-12-23 AU AU2010338305A patent/AU2010338305A1/en not_active Abandoned
- 2010-12-23 RU RU2012131099/15A patent/RU2012131099A/ru unknown
- 2010-12-23 CN CN201080059591XA patent/CN102686241A/zh active Pending
- 2010-12-23 EP EP10795400A patent/EP2519262A2/en not_active Withdrawn
- 2010-12-23 JP JP2012546422A patent/JP2013515754A/ja active Pending
- 2010-12-23 BR BR112012013148A patent/BR112012013148A2/pt not_active IP Right Cessation
- 2010-12-27 AR ARP100104954A patent/AR079746A1/es unknown
- 2010-12-27 TW TW099146170A patent/TW201200152A/zh unknown
-
2012
- 2012-05-03 IL IL219592A patent/IL219592A0/en unknown
- 2012-06-11 ZA ZA2012/04266A patent/ZA201204266B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2013515754A (ja) | 2013-05-09 |
| MX2012007676A (es) | 2012-08-03 |
| SG182304A1 (en) | 2012-08-30 |
| ZA201204266B (en) | 2014-11-26 |
| US20110158987A1 (en) | 2011-06-30 |
| WO2011080209A3 (en) | 2012-03-15 |
| EP2519262A2 (en) | 2012-11-07 |
| CA2783715A1 (en) | 2011-07-07 |
| TW201200152A (en) | 2012-01-01 |
| KR20120110175A (ko) | 2012-10-09 |
| CN102686241A (zh) | 2012-09-19 |
| RU2012131099A (ru) | 2014-02-10 |
| IL219592A0 (en) | 2012-06-28 |
| BR112012013148A2 (pt) | 2017-03-21 |
| WO2011080209A2 (en) | 2011-07-07 |
| AU2010338305A1 (en) | 2012-05-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR079746A1 (es) | Formulacion farmaceutica de anticuerpo | |
| AR124140A2 (es) | Formulaciones de anticuerpos | |
| NZ719036A (en) | Anti-pdl1 antibody formulations | |
| AR078161A1 (es) | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. | |
| CO6251275A2 (es) | Formulaciones de inmunoglobulina liofilizadas y metodos para su preparacion | |
| AR089787A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-ang2 | |
| CY1122181T1 (el) | Φαρμακοτεχνικη μορφη αντισωματος | |
| PT2459167E (pt) | Formulação subcutânea de anticorpo anti-her2 | |
| JP2013500947A5 (es) | ||
| PE20091327A1 (es) | Composicion farmaceutica que comprende anticuerpos monoclonales | |
| RU2015111319A (ru) | Препараты антитела к рецептору анти-пролактина | |
| PE20091852A1 (es) | Formulacion farmaceutica que comprende un anticuerpo de ox40l | |
| PE20141159A1 (es) | Metodos para tratar o prevenir trastornos relacionados con el colesterol | |
| PE20181400A1 (es) | Formulacion farmaceutica acuosa del anticuerpo anti-pd-l1 avelumab | |
| TNSN08511A1 (en) | Lyophilized formulations of anti-egfr antibodies | |
| MY182680A (en) | Antibody formulation and therapeutic regimens | |
| PE20091328A1 (es) | Formulacion de anticuerpo | |
| AR082024A1 (es) | Formulacion de anticuerpo contra ox40l humano | |
| JP2013531679A5 (es) | ||
| FI3834841T3 (fi) | Stabiloituja neste- ja lyofilisoituja ADAMTS13-formulaatioita | |
| RU2019100221A (ru) | Составы на основе антитела к CD19 | |
| AR074778A1 (es) | Composicion farmaceutica, con anticuerpo monoclonal humano anti - igf-ir. | |
| MX387451B (es) | Formulacion liquida que comprende un compuesto neutralizante de gm-csf. | |
| AR083338A1 (es) | Formulaciones estabilizadas que contienen anticuerpos anti-receptor de interleucina-4 (il-4r) | |
| FI3554474T3 (fi) | Mikafungiinikoostumuksia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |